Aernoud Fiolet

223 Colchicine in chronic coronary disease in relation to history of acute coronary syndrome Central illustration. Cumulative incidence of the primary end point divided by prior ACS status. The effect of colchicine 0.5mg once daily versus placebo on the cumulative incidence of the composite end point of cardiovascular death, myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization. Subgroups divided by time since most recent prior acute coronary syndrome (ACS) at randomization, Cox proportional hazard models were used to investigate colchicine treatment effect in each subgroup, and the interaction between colchicine treatment effect and prior ACS status was assessed. The reduction of the composite end point by colchicine was consistent across the subgroups and no interaction was found, which suggests that the benefits of colchicine are consistent irrespective of time since the most recent ACS event. ACS = acute coronary syndrome; CI = confidence interval; HR = hazard ratio.